I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development, as well as a deep understanding of technological innovation in the industry. Today, we’re diving into the recent FDA approval of Gilead Sciences’ Biktarvy for expanded HIV
Imagine living with a condition where even a small bite of protein-rich food could lead to severe neurological damage, a daily reality for thousands of individuals in the U.S. diagnosed with phenylketonuria (PKU), a rare genetic metabolic disorder. Affecting approximately one in every 13,500 to
What happens when a rare cancer keeps coming back, defying every treatment thrown at it? For adults battling relapsed marginal zone lymphoma (MZL), a subtype of non-Hodgkin lymphoma, this relentless cycle has long been a harsh reality, but a flicker of hope emerges as Bristol Myers Squibb’s
Hemophilia, a rare inherited bleeding disorder impacting approximately 800,000 individuals globally, has long posed significant challenges for patients and healthcare providers due to the body's impaired ability to form blood clots. For many, the struggle to manage frequent bleeding episodes with
In a landscape where over 50% of pharmaceuticals distributed in the US are manufactured overseas, the fragility of the drug supply chain has become a pressing concern for national health security, prompting urgent action. Imagine a scenario where a global crisis disrupts access to essential
I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development, as well as a deep understanding of technological innovation in the industry. Today, we’re diving into a groundbreaking advancement in cancer treatment: the recent
